NOVIGENIX Trademark

Trademark Overview

On Friday, December 22, 2023, a trademark application was filed for NOVIGENIX with the United States Patent and Trademark Office. The USPTO has given the NOVIGENIX trademark a serial number of 98976186. The federal status of this trademark filing is STATEMENT OF USE - TO EXAMINER as of Wednesday, June 25, 2025. This trademark is owned by Novigenix SA. The NOVIGENIX trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical research services; clinical research in the fields of immunotherapy and drug development; medical and scientific research, namely, conducting, clinical trials for others; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; blood analysis services for scientific research purposes
novigenix

General Information

Serial Number98976186
Word MarkNOVIGENIX
Filing DateFriday, December 22, 2023
Status748 - STATEMENT OF USE - TO EXAMINER
Status DateWednesday, June 25, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 24, 2024

Trademark Statements

Goods and ServicesPharmaceutical research services; clinical research in the fields of immunotherapy and drug development; medical and scientific research, namely, conducting, clinical trials for others; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; blood analysis services for scientific research purposes

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, December 22, 2023
Primary Code042
First Use Anywhere DateWednesday, January 24, 2024
First Use In Commerce DateWednesday, January 24, 2024

Trademark Owner History

Party NameNovigenix SA
Party Type20 - Owner at Publication
Legal Entity Type33 - NOT AVAILABLE
AddressEpalinges 1066
CH
Party NameNovigenix SA
Party Type10 - Original Applicant
Legal Entity Type33 - NOT AVAILABLE
AddressEpalinges 1066
CH

Trademark Events

Event DateEvent Description
Friday, December 22, 2023NEW APPLICATION ENTERED
Friday, April 5, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, July 24, 2024ASSIGNED TO EXAMINER
Monday, July 29, 2024NON-FINAL ACTION WRITTEN
Monday, July 29, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, July 29, 2024NON-FINAL ACTION E-MAILED
Thursday, August 15, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, August 15, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, August 16, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, August 20, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 4, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 24, 2024PUBLISHED FOR OPPOSITION
Tuesday, September 24, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 19, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, January 27, 2025SOU EXTENSION 1 FILED
Monday, January 27, 2025SOU TEAS EXTENSION RECEIVED
Monday, February 3, 2025DIVISIONAL REQUEST RECEIVED
Monday, February 3, 2025USE AMENDMENT FILED
Monday, February 3, 2025TEAS STATEMENT OF USE RECEIVED
Monday, February 3, 2025TEAS REQUEST TO DIVIDE RECEIVED
Tuesday, February 4, 2025TEAS REQUEST TO DIVIDE RECEIVED
Wednesday, June 18, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, June 25, 2025STATEMENT OF USE PROCESSING COMPLETE
Wednesday, June 25, 2025SOU EXTENSION 1 GRANTED
Wednesday, June 25, 2025DIVISIONAL PROCESSING COMPLETE
Wednesday, June 25, 2025REVIEW OF CORRESPONDENCE COMPLETE

Related Keywords

novigenix research scientific clinical medical trials services information field blood purposes